Joshua Bauml, MD explains that small cell lung cancer has a unique etiology, course and prognosis by comparison to non-small cell lung cancer. Representing only 15% of all lung cancers, small cell lung cancers have yet to yield a key driver mutation to researchers, confounding efforts to develop biologic therapies for the disease. Dr. Bauml reviews ongoing studies at Penn to discover alternative approaches, including proofreading proteins and antibody drug conjugates.
Related Links
Published
February 7, 2017
Created by
BROADCASTMED